UTHR [NASD]
United Therapeutics Corporation
Index- P/E12.90 EPS (ttm)14.44 Insider Own0.10% Shs Outstand45.20M Perf Week2.72%
Market Cap8.34B Forward P/E9.76 EPS next Y19.09 Insider Trans-65.36% Shs Float44.42M Perf Month-0.51%
Income687.40M PEG8.60 EPS next Q4.04 Inst Own97.10% Short Float2.52% Perf Quarter-6.80%
Sales1.77B P/S4.72 EPS this Y-12.90% Inst Trans-0.24% Short Ratio2.40 Perf Half Y-6.57%
Book/sh92.40 P/B2.02 EPS next Y9.80% ROA13.50% Target Price227.62 Perf Year-2.50%
Cash/sh50.63 P/C3.68 EPS next 5Y1.50% ROE17.60% 52W Range158.38 - 218.38 Perf YTD-13.78%
Dividend- P/FCF12.39 EPS past 5Y-8.00% ROI9.20% 52W High-14.68% Beta0.62
Dividend %- Quick Ratio8.50 Sales past 5Y1.10% Gross Margin92.90% 52W Low17.63% ATR6.30
Employees965 Current Ratio8.80 Sales Q/Q21.80% Oper. Margin51.20% RSI (14)53.63 Volatility3.15% 3.68%
OptionableYes Debt/Eq0.19 EPS Q/Q724.60% Profit Margin38.90% Rel Volume0.54 Prev Close186.31
ShortableYes LT Debt/Eq0.19 EarningsMay 04 BMO Payout0.00% Avg Volume465.59K Price186.31
Recom1.70 SMA202.10% SMA502.17% SMA200-3.99% Volume0 Change0.00%
Feb-11-22Initiated BTIG Research Neutral
Jul-14-21Upgrade Argus Hold → Buy $205
Apr-26-21Resumed Credit Suisse Outperform $196
Feb-01-21Upgrade H.C. Wainwright Neutral → Buy $125 → $195
Sep-14-20Resumed JP Morgan Overweight $142
Jun-25-20Reiterated H.C. Wainwright Neutral $85 → $125
Mar-10-20Upgrade Jefferies Hold → Buy $123
Feb-27-20Upgrade Cowen Market Perform → Outperform $119 → $145
Jan-31-20Upgrade JP Morgan Neutral → Overweight $120
Dec-03-19Initiated BofA/Merrill Underperform
Aug-01-19Upgrade Ladenburg Thalmann Neutral → Buy $103 → $106
Aug-01-19Upgrade Jefferies Underperform → Hold $90
Jul-01-19Upgrade Credit Suisse Neutral → Outperform $98 → $101
May-17-19Upgrade UBS Sell → Neutral $115 → $94
May-09-19Upgrade Credit Suisse Underperform → Neutral $98
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
May-11-22 06:35AM  
May-10-22 02:26PM  
May-05-22 11:12AM  
May-04-22 02:38PM  
07:15AM  
06:00AM  
Apr-29-22 06:00AM  
Apr-27-22 03:03PM  
06:00AM  
Apr-13-22 03:04PM  
Apr-06-22 06:00AM  
Mar-14-22 02:56PM  
05:18AM  
Mar-10-22 08:26AM  
Mar-08-22 06:00AM  
Mar-01-22 06:00AM  
Feb-25-22 11:09AM  
10:45AM  
10:00AM  
12:30AM  
Feb-24-22 07:15AM  
06:00AM  
Feb-21-22 09:30AM  
06:00AM  
Feb-17-22 03:21PM  
Feb-16-22 10:58AM  
09:54AM  
Feb-15-22 05:03PM  
Feb-07-22 06:38PM  
Feb-04-22 09:38AM  
Feb-03-22 05:38PM  
02:36PM  
Jan-21-22 06:00AM  
Jan-19-22 09:38PM  
Jan-06-22 11:24AM  
07:56AM  
Jan-03-22 12:43PM  
Dec-30-21 07:25AM  
06:00AM  
Dec-28-21 02:38AM  
Dec-27-21 05:25PM  
Dec-23-21 10:15AM  
Dec-21-21 06:15PM  
Dec-19-21 05:38AM  
Dec-17-21 09:15PM  
Dec-14-21 02:57PM  
Dec-07-21 09:21PM  
Dec-04-21 02:29PM  
Dec-03-21 11:31AM  
06:00AM  
Nov-26-21 06:00AM  
Nov-22-21 10:39AM  
Nov-10-21 02:59PM  
Nov-08-21 10:28AM  
Nov-07-21 12:57PM  
Nov-04-21 09:10AM  
Nov-03-21 12:01PM  
07:15AM  
06:00AM  
Nov-01-21 06:00AM  
Oct-27-21 04:25PM  
06:00AM  
Oct-24-21 05:09AM  
Oct-21-21 06:08AM  
06:00AM  
Oct-20-21 03:03PM  
07:00AM  
01:28AM  
Oct-19-21 11:18PM  
10:29AM  
Oct-18-21 02:38PM  
11:42AM  
09:20AM  
08:45AM  
06:36AM  
06:02AM  
06:00AM  
Oct-15-21 08:49AM  
Oct-11-21 06:00AM  
Oct-05-21 01:53PM  
Oct-04-21 01:44PM  
Oct-01-21 01:49PM  
Sep-30-21 04:30PM  
Sep-10-21 06:00AM  
Sep-07-21 09:54AM  
06:00AM  
Sep-03-21 11:31AM  
Aug-25-21 06:00AM  
Aug-24-21 06:00AM  
Aug-12-21 11:30AM  
Aug-05-21 10:09AM  
Aug-04-21 05:56PM  
12:30PM  
07:15AM  
06:00AM  
Aug-03-21 06:00AM  
Jul-29-21 08:16AM  
Jul-28-21 03:03PM  
06:00AM  
Jul-21-21 10:06AM  
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATUSKY CHRISTOPHERDirectorMay 17Option Exercise63.902,000127,8003,680May 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 05Option Exercise111.006,000666,00042,397May 06 04:30 PM
DWEK RAYMONDDirectorMay 05Option Exercise48.112,00096,2202,000May 06 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 05Sale190.656,0001,143,89436,397May 06 04:30 PM
DWEK RAYMONDDirectorApr 28Option Exercise48.112,00096,2202,000Apr 29 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 21Option Exercise111.006,000666,00042,487Apr 22 04:30 PM
DWEK RAYMONDDirectorApr 21Option Exercise48.112,00096,2202,000Apr 22 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 21Sale189.186,0001,135,07836,397Apr 22 04:30 PM
DWEK RAYMONDDirectorApr 14Option Exercise48.112,00096,2202,000Apr 15 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 07Option Exercise111.006,000666,00042,487Apr 08 04:30 PM
PATUSKY CHRISTOPHERDirectorApr 07Option Exercise63.902,000127,8003,680Apr 08 04:30 PM
DWEK RAYMONDDirectorApr 07Option Exercise48.112,00096,2202,000Apr 08 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 07Sale185.526,0001,113,09536,487Apr 08 04:30 PM
Thompson Tommy GDirectorMar 29Option Exercise48.111,50072,1658,020Mar 30 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 17Option Exercise111.006,000666,00042,487Mar 18 04:30 PM
Thompson Tommy GDirectorMar 17Option Exercise48.111,50972,5988,029Mar 18 04:36 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 17Sale182.426,0001,094,50136,487Mar 18 04:30 PM
Thompson Tommy GDirectorMar 16Option Exercise48.111,50072,1658,020Mar 18 04:36 PM
Thompson Tommy GDirectorMar 15Option Exercise48.111,50072,1658,020Mar 16 04:35 PM
PATUSKY CHRISTOPHERDirectorMar 15Option Exercise88.032,000176,0603,680Mar 16 04:35 PM
Thompson Tommy GDirectorMar 10Option Exercise48.111,00048,1107,520Mar 11 04:35 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 03Option Exercise111.006,000666,00042,369Mar 04 04:35 PM
Thompson Tommy GDirectorMar 03Option Exercise48.111,50072,1658,020Mar 04 04:33 PM
MAHON PAUL AEVP & GENERAL COUNSELMar 03Sale174.126,0001,044,71536,369Mar 04 04:35 PM
MAHON PAUL AEVP & GENERAL COUNSELFeb 17Option Exercise111.006,000666,00036,369Feb 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELFeb 17Sale202.176,0001,213,02430,369Feb 18 04:30 PM
MAHON PAUL AEVP & General CounselFeb 03Option Exercise111.006,000666,00036,369Feb 04 04:30 PM
MAHON PAUL AEVP & General CounselFeb 03Sale200.106,0001,200,61630,369Feb 04 04:30 PM
MAHON PAUL AEVP & General CounselJan 20Option Exercise111.006,000666,00036,369Jan 21 04:31 PM
MAHON PAUL AEVP & General CounselJan 20Sale205.576,0001,233,44030,369Jan 21 04:31 PM
MAHON PAUL AEVP & General CounselJan 06Sale192.466,0001,154,78730,369Jan 06 05:08 PM
ROTHBLATT MARTINE AChairperson & CEODec 29Option Exercise53.423,082164,6403,212Dec 29 04:31 PM
ROTHBLATT MARTINE AChairperson & CEODec 29Sale212.493,082654,894130Dec 29 04:31 PM
ROTHBLATT MARTINE AChairperson & CEODec 27Option Exercise53.423,082164,6403,212Dec 27 04:48 PM
ROTHBLATT MARTINE AChairperson & CEODec 27Sale213.313,082657,421130Dec 27 04:48 PM
ROTHBLATT MARTINE AChairperson & CEODec 22Option Exercise53.423,082164,6403,212Dec 22 05:45 PM
ROTHBLATT MARTINE AChairperson & CEODec 22Sale202.443,082623,920130Dec 22 05:45 PM
BENKOWITZ MICHAELPresident and COODec 21Option Exercise61.062,400146,5444,635Dec 22 04:32 PM
ROTHBLATT MARTINE AChairperson & CEODec 20Option Exercise53.423,082164,6403,212Dec 21 04:47 PM
ROTHBLATT MARTINE AChairperson & CEODec 20Sale200.003,082616,400130Dec 21 04:47 PM
MAHON PAUL AEVP & General CounselDec 16Option Exercise111.006,000666,00042,369Dec 17 04:32 PM
BENKOWITZ MICHAELPresident and COODec 16Option Exercise61.064,000244,2406,235Dec 17 04:30 PM
MAHON PAUL AEVP & General CounselDec 16Sale195.536,0001,173,17136,369Dec 17 04:32 PM
BENKOWITZ MICHAELPresident and COODec 14Option Exercise61.064,000244,2406,235Dec 15 04:32 PM
BENKOWITZ MICHAELPresident and COODec 07Option Exercise61.064,000244,2406,235Dec 08 05:02 PM
MAHON PAUL AEVP & General CounselDec 02Option Exercise111.006,000666,00042,369Dec 02 04:30 PM
MAHON PAUL AEVP & General CounselDec 02Sale189.366,0001,136,14036,369Dec 02 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 24Option Exercise53.423,083164,6943,213Nov 29 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 24Sale200.643,083618,573130Nov 29 04:30 PM
BENKOWITZ MICHAELPresident and COONov 23Option Exercise61.064,000244,2406,235Nov 24 04:30 PM
ROTHBLATT MARTINE AChairperson & CEONov 22Option Exercise53.423,083164,6943,213Nov 24 04:31 PM
ROTHBLATT MARTINE AChairperson & CEONov 22Sale200.423,083617,895130Nov 24 04:31 PM
MAHON PAUL AEVP & General CounselNov 18Option Exercise111.006,000666,00042,369Nov 18 04:47 PM
BENKOWITZ MICHAELPresident and COONov 18Option Exercise53.834,000215,3206,235Nov 19 04:57 PM
ROTHBLATT MARTINE AChairperson & CEONov 17Option Exercise53.423,083164,6943,213Nov 17 05:41 PM
ROTHBLATT MARTINE AChairperson & CEONov 17Sale201.903,083622,458130Nov 17 05:41 PM
BENKOWITZ MICHAELPresident and COONov 16Option Exercise53.834,000215,3206,235Nov 17 05:40 PM
ROTHBLATT MARTINE AChairman & CEONov 15Option Exercise53.423,083164,6943,213Nov 15 04:35 PM
ROTHBLATT MARTINE AChairman & CEONov 15Sale203.453,083627,236130Nov 15 04:35 PM
PATUSKY CHRISTOPHERDirectorNov 11Option Exercise63.902,000127,8003,680Nov 12 04:35 PM
BENKOWITZ MICHAELPresident and COONov 11Option Exercise53.834,000215,3206,235Nov 12 04:33 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise53.423,083164,6943,213Nov 10 04:33 PM
ROTHBLATT MARTINE AChairman & CEONov 10Sale200.003,083616,600130Nov 10 04:33 PM
BENKOWITZ MICHAELPresident and COONov 09Option Exercise53.834,000215,3206,235Nov 10 04:34 PM
DWEK RAYMONDDirectorNov 08Option Exercise48.113,000144,3303,000Nov 08 06:51 PM
ROTHBLATT MARTINE AChairman & CEONov 08Option Exercise53.423,083164,6943,213Nov 08 04:32 PM
PATUSKY CHRISTOPHERDirectorNov 08Sale200.162,300460,3681,680Nov 08 04:30 PM
ROTHBLATT MARTINE AChairman & CEONov 08Sale200.943,083619,498130Nov 08 04:32 PM
ROTHBLATT MARTINE AChairman & CEONov 04Option Exercise53.423,083164,6943,213Nov 05 04:33 PM
BENKOWITZ MICHAELPresident and COONov 04Option Exercise53.834,000215,3206,235Nov 05 04:31 PM
MAHON PAUL AEVP & General CounselNov 04Option Exercise111.006,000666,00042,369Nov 04 04:31 PM
MAHON PAUL AEVP & General CounselNov 04Sale201.196,0001,207,15336,369Nov 04 04:31 PM
ROTHBLATT MARTINE AChairman & CEONov 04Sale200.003,083616,600130Nov 05 04:33 PM
BENKOWITZ MICHAELPresident and COONov 02Option Exercise53.834,000215,3206,235Nov 03 04:37 PM
BENKOWITZ MICHAELPresident and COOOct 28Option Exercise53.834,000215,3206,235Oct 29 04:31 PM
BENKOWITZ MICHAELPresident and COOOct 26Option Exercise53.834,000215,3206,235Oct 27 04:32 PM
BENKOWITZ MICHAELPresident and COOOct 21Option Exercise53.834,000215,3206,235Oct 22 04:30 PM
MAHON PAUL AEVP & General CounselOct 21Option Exercise111.006,000666,00042,369Oct 21 04:30 PM
MAHON PAUL AEVP & General CounselOct 21Sale190.186,0001,141,08236,369Oct 21 04:30 PM
BENKOWITZ MICHAELPresident and COOOct 07Option Exercise53.834,000215,3206,235Oct 08 05:08 PM
MAHON PAUL AEVP & General CounselOct 07Option Exercise111.006,000666,00042,369Oct 07 04:31 PM
MAHON PAUL AEVP & General CounselOct 07Sale190.526,0001,143,14436,369Oct 07 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 23Option Exercise53.834,000215,3206,235Sep 24 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 21Option Exercise53.834,000215,3206,235Sep 22 04:37 PM
BENKOWITZ MICHAELPresident and COOSep 16Option Exercise53.834,000215,3206,235Sep 17 04:39 PM
MAHON PAUL AEVP & General CounselSep 16Option Exercise111.006,000666,00042,369Sep 16 04:31 PM
MAHON PAUL AEVP & General CounselSep 16Sale204.086,0001,224,46736,369Sep 16 04:31 PM
BENKOWITZ MICHAELPresident and COOSep 14Option Exercise53.834,000215,3206,235Sep 15 04:33 PM
BENKOWITZ MICHAELPresident and COOSep 09Option Exercise53.834,000215,3206,235Sep 10 05:39 PM
BENKOWITZ MICHAELPresident and COOSep 07Option Exercise53.834,000215,3206,235Sep 08 06:19 PM
BENKOWITZ MICHAELPresident and COOSep 02Option Exercise53.834,000215,3206,235Sep 02 05:24 PM
MAHON PAUL AEVP & General CounselSep 02Option Exercise111.006,000666,00042,369Sep 02 05:25 PM
MAHON PAUL AEVP & General CounselSep 02Sale210.946,0001,265,65036,369Sep 02 05:25 PM
BENKOWITZ MICHAELPresident and COOAug 31Option Exercise53.834,000215,3206,235Sep 01 04:31 PM
BENKOWITZ MICHAELPresident and COOAug 26Option Exercise53.834,000215,3206,235Aug 27 04:32 PM
BENKOWITZ MICHAELPresident and COOAug 24Option Exercise53.834,000215,3206,235Aug 24 06:27 PM
MAHON PAUL AEVP & General CounselAug 23Option Exercise111.006,000666,00042,369Aug 24 04:33 PM
MAHON PAUL AEVP & General CounselAug 23Sale205.826,0001,234,90136,369Aug 24 04:33 PM
BENKOWITZ MICHAELPresident and COOAug 19Option Exercise53.834,000215,3206,235Aug 20 04:31 PM
BENKOWITZ MICHAELPresident and COOAug 17Option Exercise53.834,000215,3206,235Aug 18 04:31 PM